EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Historicising the “Empty Pipeline”: How Antibiotic Innovation Became a Market Failure (1980–2024)

Nadya Wells, Mirza Yanira Alas Portillo, Erin Lindsey Paterson, Frédéric Vagneron, Claas Kirchhelle

Public Humanities · 2025 · 1

DOI: 10.1017/pub.2025.10067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Public Humanities, online erschienen am 21.11.2025. Verfasst von Nadya Wells und 4 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: British Academy, Norges Forskningsråd, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibiotic innovation has slowed. Despite substantial public investment, research and development (R&D) remains insufficient to address rising antimicrobial resistance (AMR). In this historical review, we draw on quantitative and qualitative historiographic methodologies, as well as on testimony from key stakeholders, to reconstruct antibiotic innovation challenges and public interventions since 1980. Emerging in the 1990s and gaining traction around 2010, the “empty antibiotic pipeline” metaphor, as well as its market failure diagnosis, has played a key role in structuring the global R&D response. This reframing described AMR as an incentives-based innovation challenge, which suited industrial and high-income country interests. However, the introduction of so-called push and pull incentives has so far failed to halt the exit of large developers, sustain diversified R&D ecosystems, or address global access challenges. This article explores challenges and conflicts involved in the implementation of the incentives-based innovation approach alongside the ever-greater subsidies required to stabilise small and medium-sized enterprises (SMEs) and attract larger pharmaceutical companies and investment from financial markets. Several SME bankruptcies since 2019 and the mothballing of novel compounds suggest that this is an unsustainable innovation model. This article also explores whether public interventions have been insufficient or whether there is a deeper problem with the central metaphor structuring global action.

Förderung

  • British Academy
  • Norges Forskningsråd
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Zitieren

APA

Wells, N., Portillo, M. Y. A., Paterson, E. L., Vagneron, F., & Kirchhelle, C. (2025). Historicising the “Empty Pipeline”: How Antibiotic Innovation Became a Market Failure (1980–2024). Public Humanities, 1. https://doi.org/10.1017/pub.2025.10067

Vancouver

Wells N, Portillo MYA, Paterson EL, Vagneron F, Kirchhelle C. Historicising the “Empty Pipeline”: How Antibiotic Innovation Became a Market Failure (1980–2024). Public Humanities. 2025;1. doi:10.1017/pub.2025.10067

BibTeX
@article{Wells2025,
  author = {Wells, Nadya and Portillo, Mirza Yanira Alas and Paterson, Erin Lindsey and Vagneron, Frédéric and Kirchhelle, Claas},
  title = {Historicising the “Empty Pipeline”: How Antibiotic Innovation Became a Market Failure (1980–2024)},
  journal = {Public Humanities},
  year = {2025},
  volume = {1},
  doi = {10.1017/pub.2025.10067}
}
Kostenlos starten →